CNTA — Centessa Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $6.13bn
- $5.95bn
- $15.00m
Annual cashflow statement for Centessa Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -381 | -216 | -151 | -236 | -198 |
| Depreciation | |||||
| Non-Cash Items | 252 | 21.2 | 33.4 | 68.3 | 30.6 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -5.83 | -5.69 | -43.5 | 24.5 | -27.8 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -135 | -201 | -160 | -142 | -194 |
| Capital Expenditures | -0.186 | -1.14 | -0.169 | -0.034 | -0.371 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 63.4 | 0.206 | -127 | 31.3 | -418 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 63.3 | -0.931 | -127 | 31.3 | -419 |
| Financing Cash Flow Items | -0.283 | -0.261 | 0 | -5.32 | -5.19 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 660 | 0.457 | 21.1 | 365 | 292 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 590 | -201 | -266 | 255 | -321 |